Estimate some biochemical tests and TGF-Β (+869 C/T) polymorphism in patients with prostate cancer

The current research sought to assess hepatic and renal functions as well as investigate the relationship between prostate cancer and the TGF-β (+869 C/T) polymorphism. A total of (80) males with prostate cancer were involved in this research. The patients were between the ages of 25 and 70. These patients were hospitalized to Kirkuk oncology center between January to March (2022). 50 healthy individuals served as the control group in this experiment. Electrophoresis is used identify DNA fragments after extraction or to detect PCR results if standard DNA is present. According to the study's findings, the patients' creatinine level (2.17±0.35) increased significantly (P≤0.05) when compared to the control group (0.93±0.28). the urea level in the patients group (52.91±4.57) increased significantly (P≤0.05) when compared to the control group (21.52±1.84). About the liver enzymes, ALT level in the patients (43.42±8.29) was significantly (P≤0.05) higher than that of the control group (16.03±1.64). AST level was seen a significant (P≤0.05) rise in the patient group (49.72±6.53) compared to the control group (20.42±2.54). Finally, this work identifies a mechanism for prostate cancer's constitutive stimulation of TGF-β signalling. The secondary structures of the mRNA, the signal peptide, and the resulting instability of the mRNA were also connected to the SNPs.